Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The American Headache Society previously published a Consensus Statement on the use of newly introduced treatments for adults with migraine. This update, which is based on the expanded evidence base and emerging expert consensus concerning postapproval usage, provides practical recommendations in the absence of a formal guideline.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This update involved four steps: (1) review of data about the efficacy, safety, and clinical use of migraine treatments introduced since the previous Statement was published; (2) incorporation of these data into a proposed update; (3) review and commentary by the Board of Directors of the American Headache Society and patients and advocates associated with the American Migraine Foundation; (4) consideration of these collective insights and integration into an updated Consensus Statement.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Since the last Consensus Statement, no evidence has emerged to alter the established principles of either acute or preventive treatment. Newly introduced acute treatments include two small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists (ubrogepant, rimegepant); a serotonin (5-HT<sub>1F</sub>) agonist (lasmiditan); a nonsteroidal anti-inflammatory drug (celecoxib oral solution); and a neuromodulatory device (remote electrical neuromodulation). New preventive treatments include an intravenous anti-CGRP ligand monoclonal antibody (eptinezumab). Several modalities, including neuromodulation (electrical trigeminal nerve stimulation, noninvasive vagus nerve stimulation, single-pulse transcranial magnetic stimulation) and biobehavioral therapy (cognitive behavioral therapy, biofeedback, relaxation therapies, mindfulness-based therapies, acceptance and commitment therapy) may be appropriate for either acute and/or preventive treatment; a neuromodulation device may be appropriate for acute migraine treatment only (remote electrical neuromodulation). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The integration of new treatments into clinical practice should be informed by the potential for benefit relative to established therapies, as well as by the characteristics and preferences of individual patients.</p></section>

Advancements in pediatric headache

Beyond pain control: Outcome and treatment preferences in pediatric migraine

New Daily Persistent Headache in the Pediatric and Adolescent Population: An Updated Review

Nonpharmacologic Treatment Options in Pediatric Tension-Type Headache Patients: A Systematic Review

An update on migraine

Headache trajectories in children and adolescents with new onset continuous headache

Headaches in Pediatric Patients during the Past Decade: Comparative Analysis by Age Group from a Multicenter Study in Korea

Triptans in the Acute Migraine Management of Children and Adolescents: An Update

[Advances in Headache and Future Prospects]

Subsume Pediatric Headaches in Psychiatric Disorders? Critiques on Delphic Nosology, Diagnostic Conundrums, and Variability in the Interventions

Headaches and adolescents: why so many failures in their management

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

The Use of Botulinum Toxin Type A in Medically Refractory Pediatric Patients With Chronic Daily Headaches and Its Impact on the Quality of Life

Non-Pharmacological Treatments in Paediatric Migraine

Diagnosis, Management, and Treatment in Pediatric Headache

Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis

Documentation of International Classification of Headache Disorders Criteria in Patient Medical Records: A Retrospective Cohort Analysis

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

Posttraumatic headache in pediatrics: an update and review

Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies

International Headache Society global practice recommendations for the acute pharmacological treatment of migraine